Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference

J Antimicrob Chemother. 2017 Jun 1;72(6):1842-1844. doi: 10.1093/jac/dkx055.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents / pharmacokinetics*
  • Anti-HIV Agents / therapeutic use
  • Cobicistat / pharmacokinetics*
  • Cobicistat / therapeutic use
  • Cytochrome P-450 CYP3A Inhibitors / pharmacokinetics*
  • Cytochrome P-450 CYP3A Inhibitors / therapeutic use
  • Darunavir / pharmacokinetics*
  • Darunavir / therapeutic use
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • HIV Integrase Inhibitors / pharmacokinetics*
  • HIV Integrase Inhibitors / therapeutic use
  • HIV Protease Inhibitors / pharmacokinetics*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / drug effects
  • Heterocyclic Compounds, 3-Ring / pharmacokinetics*
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Oxazines
  • Piperazines
  • Pyridones
  • Ritonavir / pharmacokinetics*
  • Ritonavir / therapeutic use

Substances

  • Anti-HIV Agents
  • Cytochrome P-450 CYP3A Inhibitors
  • HIV Integrase Inhibitors
  • HIV Protease Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir
  • Cobicistat
  • Ritonavir
  • Darunavir